📚 Part of the TILA-278 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Chemistry, manufacturing and controls document for TILA-278.
Why it exists. Chemistry, manufacturing, and controls evidence establishing product quality and consistency.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH Q6B / Q8-Q11 / Q14
| Field | Value |
|---|---|
| Document ID | M3-CS |
| Version | 1.0 |
| Compound | TILA-278 (anti-TL1A antagonist / IL-22R agonist bispecific) |
| Standard | ICH Q6B / Q8-Q11 / Q14 |
| Confidentiality | Confidential |
Chemistry, manufacturing and controls document for TILA-278.
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-07-08 | CMC/Quality | Initial issue |
No comments yet. Be the first to say something!
This section presents the integrated control strategy and the drug-substance (DS) and drug-product (DP) specifications for TILA-278, a recombinant humanized IgG1 bispecific monoclonal antibody administered subcutaneously (SC) for the treatment of moderate-to-severe ulcerative colitis (UC). One antigen-binding arm is an antagonist of TL1A (TNFSF15); the second arm is an agonist of the interleukin-22 receptor (IL-22R, the IL-22RA1/IL-10RB heterodimer). The two functionalities are complementary: TL1A antagonism dampens TH1/TH17-driven mucosal inflammation and intestinal fibrosis, while IL-22R agonism drives epithelial regeneration and mucosal-barrier repair.
Because TILA-278 exerts two independent, mechanistically distinct pharmacologic activities from a single molecular entity, the control strategy is designed to assure that (i) each functional arm is present, correctly assembled, and biologically active; (ii) the correct heterodimeric (bispecific) species predominates over product-related mispaired variants; and (iii) product-, process-, and safety-related attributes are maintained within ranges qualified by nonclinical and clinical experience — in particular by the material used in the pivotal induction study TILA278-201.
The control strategy and specifications are established in accordance with ICH Q6B (specifications and acceptance criteria for biotechnological/biological products), ICH Q8(R2), Q9(R1), Q10 and Q11 (pharmaceutical/biotech development, quality risk management, quality systems, and DS development and manufacture), and ICH Q14 together with Q2(R2) (analytical procedure development and validation). Attribute risk ranking follows the enhanced (QbD) principles of Q8/Q9; the resulting Critical Quality Attributes (CQAs) are controlled by an integrated combination of the manufacturing process, in-process controls (IPCs), characterization testing, and release/stability specifications.
Consistent with ICH Q10, the control strategy for TILA-278 is not synonymous with the release specification. Assurance of quality is distributed across multiple, mutually reinforcing layers, with release testing constituting the final confirmatory layer rather than the sole control point:
The QTPP anchors CQA identification and specification setting.
| QTPP element | Target |
|---|---|
| Dosage form | Sterile solution for SC injection |
| Container/closure | Single-use prefilled syringe (PFS) and PFS-based autoinjector |
| Route | Subcutaneous |
| Strength / fill | 450 mg per device at a nominal protein concentration of 150 mg/mL |
| Molecular format | Humanized IgG1 bispecific mAb; anti-TL1A antagonist arm + IL-22R agonist arm; obligate heterodimer |
| Potency | Both mechanisms functional: TL1A neutralization and IL-22R agonism within qualified ranges |
| Purity/impurities | Monomeric bispecific predominant; aggregates, fragments, charge/glycan variants, mispaired species controlled |
| Safety attributes | Process- and product-related impurities, adventitious agents, endotoxin, sterility, and subvisible particulates within safe limits |
| Stability / shelf life | months refrigerated (2–8 °C) with defined in-use/excursion allowances |
| Immunogenicity | Attributes influencing immunogenicity risk (aggregates, particulates, glycation, sequence variants) minimized |
CQAs were identified via a structured quality risk assessment (ICH Q9(R1)) that scored each candidate attribute for its potential impact on safety (including immunogenicity), efficacy/potency, pharmacokinetics/exposure, and detectability/uncertainty. Attributes were ranked High/Medium/Low criticality; all High and selected Medium attributes are subject to specification and/or dedicated in-process control.
| Attribute | Primary impact domain | Criticality | Principal control point(s) |
|---|---|---|---|
| Anti-TL1A neutralizing potency | Efficacy | High | DS + DP release, stability |
| IL-22R agonist potency | Efficacy | High | DS + DP release, stability |
| Correct heterodimer / bispecific content | Efficacy, PK, immunogenicity | High | DS release (LC-MS/HIC), process control |
| Mispaired / homodimer / half-antibody species | Efficacy, immunogenicity | High | DS release, downstream process |
| Aggregates (HMW) | Immunogenicity, safety, efficacy | High | DS + DP release, stability, IPC |
| Fragments (LMW) | Efficacy, PK | Medium | DS + DP release, stability |
| Charge variants (acidic/basic) | Efficacy, PK | Medium | DS + DP release, stability |
| N-glycosylation (afucosylation, high-mannose, galactosylation, sialylation) | PK, effector function, potency | Medium–High | DS release / characterization, process |
| Host cell protein (HCP) | Safety, immunogenicity | High | DS release, downstream process, IPC |
| Residual DNA | Safety | High | DS release, downstream process |
| Residual Protein A | Safety, immunogenicity | Medium | DS release, IPC |
| Endotoxin / bioburden | Safety | High | DS + DP release, IPC |
| Sterility / container-closure integrity | Safety | High | DP release, stability, aseptic validation |
| Subvisible/visible particulates | Safety, immunogenicity | High | DP release, stability |
| Polysorbate content | Stability (interfacial protection) | Medium | DP release, stability |
| Protein concentration / deliverable dose | Efficacy (dose) | High | DS + DP release |
The following linkage table summarizes, at the level of detail appropriate to this control-strategy overview, how each principal CQA is assured through Critical Process Parameters (CPPs), IPCs, and release testing. Detailed process descriptions and proven acceptable ranges reside in 3.2.S.2.2–3.2.S.2.4 and 3.2.P.3.3–3.2.P.3.5.
| CQA | Key CPP(s) | In-process control (IPC) | Release/characterization control |
|---|---|---|---|
| Aggregates (HMW) | Cell-culture duration/temperature; polishing gradient and load; UF/DF concentration and shear | Post-polishing pool % HMW (SEC); in-process hold-time and temperature limits | SEC-HPLC at DS and DP release and on stability |
| Correct heterodimer content | Assembly/expression conditions; polishing selectivity | Pool heterodimer content / mispairing (IPC by HIC or intact LC-MS) | Intact/subunit LC-MS and HIC at DS release |
| Charge variants | Cell-culture pH/duration; harvest timing | Pool charge-variant profile (iCIEF) IPC | iCIEF at DS and DP release and on stability |
| N-glycosylation | Cell line, feed strategy, culture pH/DO/temperature | Pool glycan screen (afucosylation, high-mannose) | Released N-glycan map (HILIC-FLR/MS) at DS release/characterization |
| HCP | Protein A capture efficiency; polishing wash/elution | Post-capture and post-polishing HCP (ELISA) IPC | HCP ELISA at DS release |
| Residual DNA | Capture and polishing clearance; nuclease treatment | Post-capture residual DNA IPC | qPCR at DS release |
| Residual Protein A | Capture wash/elution; low-pH conditions | Post-capture leached Protein A IPC | Immunoassay at DS release |
| Viral safety | Low-pH viral inactivation time/pH; nanofiltration integrity | Inactivation hold time/pH; filter integrity test | Validated clearance (3.2.A.2); DS bioburden/endotoxin |
| Potency (both arms) | Overall process consistency; glycosylation; assembly | Pool potency (screening bioassay) where applicable | Dual bioassays at DS and DP release and on stability |
| Subvisible particulates | DP mixing/filtration/fill shear; freeze-thaw; polysorbate level | Filtration integrity; fill-line controls | USP <788> light-obscuration at DP release and on stability |
| Sterility / CCI | Aseptic processing; sterilizing-grade filtration; sealing | Pre-/post-use filter integrity; fill-weight; in-process bioburden | Sterility (USP <71>); CCIT at DP release and on stability |
| Deliverable dose | Fill volume; device assembly | Fill-weight/volume checks; device functional checks | Extractable volume, content, and device functional tests at DP release |
The obligate heterodimeric format introduces product-related species not present for a conventional monospecific mAb — homodimers of each arm, half-antibodies, and light-chain–mispaired species. Because such species can carry only one (or neither) functionality, they are simultaneously purity impurities and potency-relevant variants, and, being non-native assemblies, are treated as potential immunogenicity contributors. Correct-pairing fidelity is engineered into the molecule (heterodimerization-promoting Fc design with cognate light-chain pairing) and is controlled by the downstream polishing train; it is verified at release by intact and subunit mass spectrometry and by a resolving orthogonal method (hydrophobic-interaction chromatography, HIC). This attribute is designated High criticality and is a defining feature of the TILA-278 control strategy.
TILA-278 drug substance is a recombinant humanized IgG1 bispecific antibody expressed in CHO cells and purified by Protein A affinity capture, orthogonal polishing chromatography, and dedicated viral-clearance operations (low-pH inactivation and nanofiltration), followed by ultrafiltration/diafiltration into the DS formulation and concentration. The specification comprises identity, potency (both mechanisms), purity/product-related impurities, process-related impurities, and general/safety tests.
| Attribute | Analytical procedure | Acceptance criterion |
|---|---|---|
| Appearance (visual) | Visual | Clear to slightly opalescent, colorless to slightly yellow liquid, essentially free of visible particles |
| Color | Ph. Eur. / USP reference solutions | ≤ (reference solution) |
| Clarity/opalescence | Nephelometry | ≤ NTU |
| pH | Potentiometry | 5.8 ± 0.3 |
| Protein concentration | UV A280 (ε-based) | 150 mg/mL ± 10% of nominal |
| Identity — anti-TL1A | Ligand-binding assay | Positive (conforms to reference) |
| Identity — IL-22R | Ligand-binding assay | Positive (conforms to reference) |
| Identity — simultaneous dual binding | Bridging assay (TL1A capture / IL-22R detection) | Positive: single molecule binds both targets |
| Identity — primary structure | Peptide map (LC-UV/MS) | Consistent with reference standard |
| Identity — intact/subunit mass | LC-MS | Consistent with reference standard (expected heterodimer mass) |
| Identity — charge profile | iCIEF | Main-peak pI consistent with reference |
| Potency — TL1A neutralization | Cell-based neutralization bioassay | 80–125% relative to reference standard |
| Potency — IL-22R agonism | Cell-based reporter-gene bioassay | 70–130% relative to reference standard |
| Purity — monomer | SEC-HPLC | ≥ 97.0% monomer |
| Impurity — HMW/aggregates | SEC-HPLC | ≤ 2.5% |
| Impurity — LMW/fragments | SEC-HPLC | ≤ 1.0% |
| Purity — intact (non-reduced) | CE-SDS (non-reduced) | ≥ 95.0% main species |
| Purity — reduced | CE-SDS (reduced) | ≥ 97.0% (sum HC + LC) |
| Correct heterodimer content | Intact/subunit LC-MS; orthogonal HIC | ≥ 90.0% correctly paired bispecific |
| Mispaired / homodimer / half-antibody | HIC / LC-MS | ≤ 5.0% total |
| Charge variants — main | iCIEF | 55–75% main |
| Charge variants — acidic | iCIEF | ≤ 30% |
| Charge variants — basic | iCIEF | ≤ 15% |
| N-glycosylation — afucosylation | HILIC-FLR / LC-MS | Report result; ≤ 7.9% |
| N-glycosylation — high mannose | HILIC-FLR / LC-MS | ≤ 7.9% |
| N-glycosylation — total galactosylation (G1+G2) | HILIC-FLR / LC-MS | Report result |
| Host cell protein (HCP) | ELISA (process-specific, qualified) | ≤ 100 ng/mg |
| Residual host cell DNA | qPCR | ≤ 10 ng/mg |
| Residual Protein A | Immunoassay | ≤ 20 ng/mg |
| Bioburden | Membrane filtration (USP <61>) | ≤ 10 CFU/10 mL |
| Bacterial endotoxin | LAL / kinetic chromogenic (USP <85>) | ≤ EU/mg |
Acceptance criteria were established from the combination of (i) manufacturing capability across clinical and process-consistency lots, (ii) results for the lots deployed in TILA278-201, and (iii) attribute criticality per §2.2. For High-criticality attributes with a demonstrated or plausible impact on safety, immunogenicity, or dual potency, criteria are set to bracket qualified experience; for attributes classified Medium or lower, criteria are set to assure consistency (process capability) and are reported where a clinically meaningful range has not yet been narrowed.
TILA-278 drug product is a sterile, preservative-free solution presented in a single-use prefilled syringe and an autoinjector incorporating the same primary container. The formulation comprises an aqueous buffer system with polysorbate as surfactant, at the nominal protein concentration and fill defined in the QTPP.
| Attribute | Analytical procedure | Acceptance criterion |
|---|---|---|
| Appearance (visual) | Visual | Clear to slightly opalescent, colorless to slightly yellow, essentially free of visible particles |
| Color / clarity | Ph. Eur. / USP references; nephelometry | ≤ reference / ≤ NTU |
| pH | Potentiometry | 5.8 ± 0.3 |
| Protein content | UV A280 | 150 mg/mL ± 10% (and label-claim content per device) |
| Osmolality | Freezing-point depression | ± mOsm/kg |
| Extractable / deliverable volume | Gravimetric/volumetric | ≥ label-claim deliverable volume |
| Identity — anti-TL1A | Ligand-binding assay | Positive (conforms) |
| Identity — IL-22R | Ligand-binding assay | Positive (conforms) |
| Identity — charge profile | iCIEF | Consistent with reference |
| Potency — TL1A neutralization | Cell-based neutralization bioassay | 80–125% relative to reference |
| Potency — IL-22R agonism | Cell-based reporter-gene bioassay | 70–130% relative to reference |
| Purity — monomer / HMW | SEC-HPLC | Monomer ≥ 96.0%; HMW ≤ 3.0% |
| Purity — LMW/fragments | SEC-HPLC | ≤ 1.5% |
| Purity — CE-SDS (non-reduced) | CE-SDS | ≥ 94.0% main |
| Charge variants | iCIEF | Main 55–75%; acidic ≤ 32%; basic ≤ 15% |
| Polysorbate content | RP-HPLC / mixed-micelle assay | ± 20% of nominal |
| Subvisible particulates | Light obscuration (USP <788>) | ≥10 µm: ≤ 6000/container; ≥25 µm: ≤ 600/container |
| Visible particulates | USP <790> / Ph. Eur. 2.9.20 | Essentially free of visible particles |
| Uniformity of dosage units | USP <905> (as applicable to single-dose) | Meets requirements |
| Sterility | USP <71> | No growth (sterile) |
| Bacterial endotoxin | LAL (USP <85>) | ≤ EU/mL (and ≤ EU/kg at max dose) |
| Container-closure integrity | Validated CCIT (e.g., headspace/HVLD) | Meets integrity criteria |
| Device functionality — break-loose/glide force | Force–displacement | Within N range |
| Device functionality — injection/delivery time (autoinjector) | Timed delivery | ≤ s |
DP acceptance criteria follow the DS rationale, adjusted to include DP-specific fill/finish and device attributes and to accommodate the incremental change in size-variant and particulate attributes that can occur across fill/finish, storage, and device actuation. Purity limits are set marginally wider than DS (e.g., HMW ≤3.0% at DP vs ≤2.5% at DS) to account for fill/finish and shelf-life change while remaining within the ranges qualified in TILA278-201; the DP potency ranges are held identical to DS to preserve the clinical link established by the dose-ordered efficacy above. Where release and end-of-shelf-life behavior differ (principally aggregate and charge-variant content), distinct release and shelf-life acceptance criteria are applied and are supported by the stability data underpinning the assigned shelf life.
Because TILA-278 has two independent pharmacologic activities, potency cannot be represented by a single assay. A two-assay potency strategy is implemented at both DS and DP release and on stability, each assay reflecting one arm's mechanism of action, complemented by characterization-level assays that confirm the two activities reside on a single molecule.
The dual-assay design ensures that loss of activity in either arm is independently detectable and cannot be masked. Both bioassays are stability-indicating (see §6/§7) and are the pivotal quality link to the dose-ordered clinical efficacy of TILA278-201.
Purity is controlled by orthogonal, mechanistically distinct methods that resolve the principal product-related variant classes:
Aggregates are given particular weight because of their recognized association with immunogenicity for SC-administered antibodies; their control spans process (culture and polishing CPPs), IPC (post-polishing pool SEC), release, and stability. Fragment and charge-variant limits are qualified by characterization demonstrating no adverse impact on the two binding activities or on FcRn-mediated exposure across the specified ranges.
Safety-relevant attributes are controlled through the layered strategy of §2:
Analytical procedures are developed and maintained under an ICH Q14 lifecycle framework. Each release-defining method has an Analytical Target Profile (ATP) specifying the required reportable range, accuracy, precision, specificity, and, for the potency bioassays, the relative-potency range and system-suitability/parallelism criteria. Procedures are validated per ICH Q2(R2) for the relevant characteristics (specificity, accuracy, precision/intermediate precision, linearity, range, and, where applicable, LOD/LOQ). Changes to procedures across the lifecycle are managed by pre-defined method-comparability/co-validation protocols to preserve consistency of the reportable result.
The stability-indicating nature of the control panel was established through forced-degradation studies (thermal, low/high pH, oxidative, photolytic, mechanical/agitation, and freeze–thaw stress). These studies demonstrate that SEC-HPLC, CE-SDS, iCIEF, and both potency bioassays detect and quantify the degradation pathways relevant to TILA-278, and they confirm that loss of activity in either functional arm is detected by the corresponding bioassay. Stress-induced increases in aggregate and charge-variant species correlate with the trended stability attributes, supporting the assignment of the shelf-life specification and the excursion/in-use claims.
A two-tiered reference-standard system is maintained: a primary reference standard, extensively characterized and traceable to clinical-qualification material (including the lots used in TILA278-201), and working reference standards qualified against the primary standard under a defined protocol. The reference standard is used to anchor identity, potency (both mechanisms), and charge/size-variant comparisons, ensuring continuity of the reportable value across the product lifecycle. Requalification and bridging of successive reference standards follow a pre-approved protocol to prevent drift in reported potency and purity.
Manufacturing changes are assessed for their impact on CQAs under an ICH Q5E comparability framework, using the release panel supplemented by extended characterization (higher-order structure, full glycan and charge-variant mapping, forced degradation, and orthogonal potency/binding methods). The control strategy, specifications, and analytical procedures are subject to continual review under the pharmaceutical quality system (ICH Q10): specification acceptance criteria and attribute-criticality assignments will be reassessed as additional manufacturing and clinical experience accrues (including confirmatory-phase data beyond the Phase 2b induction study TILA278-201), and any tightening or refinement will be justified against accumulated process capability and the established exposure–response relationship.
The TILA-278 control strategy is an integrated, risk-based system in which the manufacturing process, in-process controls, and DS/DP specifications jointly assure the quality attributes essential to the molecule's dual mechanism of action. Its distinguishing features are (i) a two-assay potency strategy that independently controls the anti-TL1A neutralizing and IL-22R agonist activities and links them to the dose-ordered clinical efficacy observed in TILA278-201; (ii) explicit control of correct bispecific heterodimer assembly and mispaired-species content; and (iii) conservative control of aggregates, particulates, and process-related impurities appropriate to a subcutaneously administered biologic, consistent with the favorable safety and immunogenicity profile of the pivotal study. All acceptance criteria bracket the attribute levels of nonclinically and clinically qualified material, and the analytical control approach is maintained under an ICH Q14/Q2(R2) and Q10 lifecycle framework.